Skip to content
GinjerNews

ForbesScience

Anthropic’s Drug Discovery Dreams: ‘It Is Not A Side Effort’

By Amy Feldman, Forbes Staff

Anthropic’s recent purchase of one-man firm Mithril is just the tip of the spear in how it hopes to use AI to accelerate drug development as it seeks a $1.4 trillion valuation in the public markets.

This story was published by Forbes. Read the full article on their site.

Read the full story at forbes.com(opens in a new tab)

More Science